BCR and hairy cell leukemia: If PNAs remain the established L1 treatment for symptomatic HCL patients, chemoimmunotherapy combining PNAs and rituximab is now recommended in second‐line, while immunoconjugates targeting CD22, BRAF inhibitors and BCR inhibitors should be considered for relapsed or refractory patients.17